Founded with a mission to revolutionize the management of neurodegenerative and aging-related diseases, Tranquis Therapeutics is a clinical-stage biopharmaceutical company. The company focuses on developing innovative small molecule drugs that reprogram dysfunctional cells to restore normal cell homeostasis and function. Their therapeutic candidates act as master regulators of mitochondrial and lysosomal function, targeting a broad range of central nervous system (CNS) and non-CNS indications.
Tranquis Therapeutics has attracted notable investors and key figures in the biotech industry, contributing to its rapid advancements. The company's groundbreaking approach has the potential to significantly reduce the burden of neurodegenerative diseases on patients, families, and societies worldwide. By pioneering treatments that address the underlying cellular dysfunctions, Tranquis Therapeutics is making a substantial impact in the field of medicine.
